Keyphrases
First-in-class
100%
Selinexor
100%
Relapsed or Refractory multiple Myeloma
100%
SINE Compound
100%
Epigenetic Modification
50%
Oncoprotein
50%
Overexpression
50%
Mechanism of Action
50%
Multiple Myeloma
50%
Myeloma
50%
Novel Mechanism
50%
Protease Inhibitors
50%
Poor Prognosis
50%
Refractory Disease
50%
Resistance Mechanisms
50%
Tumor Protein p53 (TP53)
50%
Therapeutic Advances
50%
Immunosuppressive Agents
50%
Drug Class
50%
Oral Agents
50%
Functional Inactivation
50%
Novel Mechanism of Action
50%
Anti-CD38 Monoclonal Antibody
50%
Cytogenetic Damage
50%
Innovative Mechanism
50%
Heavily Treated
50%
Bypass Resistance
50%
Complex Cytogenetics
50%
Medicine and Dentistry
Multiple Myeloma
100%
Selinexor
100%
Monoclonal Antibody
50%
Myeloma
50%
Proteasome Inhibitor
50%
Oncoprotein
50%
Tumor Suppressor Protein
50%
Diseases
50%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Selinexor
100%
Monoclonal Antibody
50%
Proteasome Inhibitor
50%
Tumor Suppressor Protein
50%
Myeloma
50%
Oncoprotein
50%
Diseases
50%
Immunology and Microbiology
Multiple Myeloma
100%
Monoclonal Antibody
50%
Proteasome
50%
CD38
50%